CN107708659B - External preparation for facial skin containing amino acids - Google Patents
External preparation for facial skin containing amino acids Download PDFInfo
- Publication number
- CN107708659B CN107708659B CN201680038189.0A CN201680038189A CN107708659B CN 107708659 B CN107708659 B CN 107708659B CN 201680038189 A CN201680038189 A CN 201680038189A CN 107708659 B CN107708659 B CN 107708659B
- Authority
- CN
- China
- Prior art keywords
- amino acid
- mass
- external preparation
- isoleucine
- leucine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title claims abstract description 54
- 230000001815 facial effect Effects 0.000 title claims abstract description 44
- ZENOXNGFMSCLLL-UHFFFAOYSA-N vanillyl alcohol Chemical compound COC1=CC(CO)=CC=C1O ZENOXNGFMSCLLL-UHFFFAOYSA-N 0.000 claims abstract description 56
- 229940024606 amino acid Drugs 0.000 claims abstract description 55
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 42
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 42
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract description 32
- 229960000310 isoleucine Drugs 0.000 claims abstract description 32
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 claims abstract description 28
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 22
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract description 22
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000004474 valine Substances 0.000 claims abstract description 22
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 21
- 102000016942 Elastin Human genes 0.000 claims description 19
- 108010014258 Elastin Proteins 0.000 claims description 19
- 229920002549 elastin Polymers 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 230000000694 effects Effects 0.000 abstract description 35
- 230000037303 wrinkles Effects 0.000 abstract description 28
- 230000007794 irritation Effects 0.000 abstract description 15
- -1 amino acid compound Chemical class 0.000 abstract description 4
- 235000001014 amino acid Nutrition 0.000 description 43
- 239000000203 mixture Substances 0.000 description 35
- 229960003136 leucine Drugs 0.000 description 28
- 229960004295 valine Drugs 0.000 description 28
- 206010040880 Skin irritation Diseases 0.000 description 18
- 230000036556 skin irritation Effects 0.000 description 18
- 231100000475 skin irritation Toxicity 0.000 description 18
- 239000002537 cosmetic Substances 0.000 description 15
- 238000009472 formulation Methods 0.000 description 14
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 12
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 11
- 108010087806 Carnosine Proteins 0.000 description 11
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 11
- 229940044199 carnosine Drugs 0.000 description 11
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 11
- 108010085443 Anserine Proteins 0.000 description 10
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 description 10
- 229930182844 L-isoleucine Natural products 0.000 description 10
- 235000019454 L-leucine Nutrition 0.000 description 10
- 239000004395 L-leucine Substances 0.000 description 10
- 241000210053 Potentilla elegans Species 0.000 description 10
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical compound CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- 238000013329 compounding Methods 0.000 description 9
- 239000006071 cream Substances 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 229920001577 copolymer Polymers 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000000284 extract Substances 0.000 description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- 235000019437 butane-1,3-diol Nutrition 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 229960002216 methylparaben Drugs 0.000 description 6
- FWFUWXVFYKCSQA-UHFFFAOYSA-M sodium;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C FWFUWXVFYKCSQA-UHFFFAOYSA-M 0.000 description 6
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000002562 thickening agent Substances 0.000 description 5
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 4
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 4
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 4
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 4
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 235000009697 arginine Nutrition 0.000 description 4
- BQMNFPBUAQPINY-UHFFFAOYSA-N azane;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonic acid Chemical compound [NH4+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C BQMNFPBUAQPINY-UHFFFAOYSA-N 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 229950006780 n-acetylglucosamine Drugs 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 229960005323 phenoxyethanol Drugs 0.000 description 4
- BXOCHUWSGYYSFW-HVWOQQCMSA-N spilanthol Chemical compound C\C=C\C=C/CC\C=C\C(=O)NCC(C)C BXOCHUWSGYYSFW-HVWOQQCMSA-N 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 3
- PQUXFUBNSYCQAL-UHFFFAOYSA-N 1-(2,3-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(F)=C1F PQUXFUBNSYCQAL-UHFFFAOYSA-N 0.000 description 3
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 3
- VLDFMKOUUQYFGF-UHFFFAOYSA-N 4-(butoxymethyl)-2-methoxyphenol Chemical compound CCCCOCC1=CC=C(O)C(OC)=C1 VLDFMKOUUQYFGF-UHFFFAOYSA-N 0.000 description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 230000002929 anti-fatigue Effects 0.000 description 3
- 229940075507 glyceryl monostearate Drugs 0.000 description 3
- 229940041616 menthol Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 229940055577 oleyl alcohol Drugs 0.000 description 3
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 3
- 229940047670 sodium acrylate Drugs 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940078465 vanillyl butyl ether Drugs 0.000 description 3
- CRBBOOXGHMTWOC-NPDDRXJXSA-N 1,4-Anhydro-6-O-dodecanoyl-2,3-bis-O-(2-hydroxyethyl)-D-glucitol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](OCCO)[C@H]1OCCO CRBBOOXGHMTWOC-NPDDRXJXSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 241001071795 Gentiana Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BLILOGGUTRWFNI-UHFFFAOYSA-N Monomenthyl succinate Chemical compound CC(C)C1CCC(C)CC1OC(=O)CCC(O)=O BLILOGGUTRWFNI-UHFFFAOYSA-N 0.000 description 2
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- BXOCHUWSGYYSFW-UHFFFAOYSA-N all-trans spilanthol Natural products CC=CC=CCCC=CC(=O)NCC(C)C BXOCHUWSGYYSFW-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 150000005693 branched-chain amino acids Chemical class 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 229960003646 lysine Drugs 0.000 description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 2
- 235000019477 peppermint oil Nutrition 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229960002898 threonine Drugs 0.000 description 2
- 239000000606 toothpaste Substances 0.000 description 2
- 229940034610 toothpaste Drugs 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- VNQXSTWCDUXYEZ-UHFFFAOYSA-N 1,7,7-trimethylbicyclo[2.2.1]heptane-2,3-dione Chemical compound C1CC2(C)C(=O)C(=O)C1C2(C)C VNQXSTWCDUXYEZ-UHFFFAOYSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- OPJWPPVYCOPDCM-UHFFFAOYSA-N 2-ethylhexyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC OPJWPPVYCOPDCM-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- GNKZMNRKLCTJAY-UHFFFAOYSA-N 4'-Methylacetophenone Chemical compound CC(=O)C1=CC=C(C)C=C1 GNKZMNRKLCTJAY-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- CMVNWVONJDMTSH-UHFFFAOYSA-N 7-bromo-2-methyl-1h-quinazolin-4-one Chemical compound C1=CC(Br)=CC2=NC(C)=NC(O)=C21 CMVNWVONJDMTSH-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- NMAQSOQOKDHXGW-NOVBDOAMSA-N C(CCCCCCCCCCCCCCCCC)(=O)O.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C(CCCCCCCCCCCCCCCCC)(=O)O.C(CCCCCCCCCCCCCCCCC)(=O)O.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO Chemical compound C(CCCCCCCCCCCCCCCCC)(=O)O.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C(CCCCCCCCCCCCCCCCC)(=O)O.C(CCCCCCCCCCCCCCCCC)(=O)O.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO NMAQSOQOKDHXGW-NOVBDOAMSA-N 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 240000000366 Melilotus officinalis Species 0.000 description 1
- 235000017822 Melilotus officinalis Nutrition 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 101100128278 Mus musculus Lins1 gene Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- GJJYQFPADNKBDY-UHFFFAOYSA-N Sabinol Natural products C=C1CCC2(C(C)C)C1(O)C2 GJJYQFPADNKBDY-UHFFFAOYSA-N 0.000 description 1
- 241000269851 Sarda sarda Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 229940089116 arnica extract Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 229940106010 beheneth-25 Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 235000013614 black pepper Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229930006711 bornane-2,3-dione Natural products 0.000 description 1
- ULBTUVJTXULMLP-UHFFFAOYSA-N butyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCC ULBTUVJTXULMLP-UHFFFAOYSA-N 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229940007061 capsicum extract Drugs 0.000 description 1
- 239000001943 capsicum frutescens fruit extract Substances 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 229940002508 ginger extract Drugs 0.000 description 1
- 235000020708 ginger extract Nutrition 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229940083256 peripheral vasodilators nicotinic acid and derivative Drugs 0.000 description 1
- 235000020744 piper nigrum extract Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- MDFQXBNVOAKNAY-HWOCKDDLSA-N sabinol Chemical compound C([C@@H](O)C1=C)C2(C(C)C)C1C2 MDFQXBNVOAKNAY-HWOCKDDLSA-N 0.000 description 1
- 229940119485 safflower extract Drugs 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
Disclosed is an amino acid-containing external preparation for facial skin, which is blended with an amino acid compound that has low irritation and a high effect of improving facial wrinkles including the periphery of the eye. An external preparation for facial skin containing an amino acid, which comprises: (A) amino acids (A) are valine, leucine and isoleucine, and vanillyl alcohol butyl ether (B). The amino acid (A) preferably contains valine 0.1-2.0 mass%, leucine 0.1-4.0 mass%, and isoleucine 0.1-2.0 mass%, and preferably contains vanillyl alcohol butyl ether (B) 0.001-1.0 mass%.
Description
Technical Field
The present invention relates to an external preparation for facial skin containing an amino acid, and more particularly, to an external preparation for facial skin containing an amino acid, which is low in irritation and has a high effect of improving facial wrinkles including the periphery of the eye.
Background
Valine, leucine and isoleucine are one of essential amino acids called Branched Chain Amino Acids (BCAAs), and have been conventionally incorporated in foods for the purpose of anemia of motility and recovery from fatigue. Further, since it is a component constituting human epidermal protein, it is also blended in external preparations such as cosmetics and medicines.
For example, patent document 1 discloses a solid solution of 3 amino acids, valine, isoleucine and leucine, for food use; patent document 2 discloses an oral amino acid composition for improving skin conditions, which is characterized by containing 5 amino acids, i.e., L-arginine, L-glutamic acid, L-valine, L-isoleucine and L-leucine, in proportions of 10 to 40 parts by weight, 5 to 20 parts by weight, 8 to 30 parts by weight and 10 to 35 parts by weight, respectively.
In addition, as an application of an external preparation, patent document 3 discloses a collagen production promoter comprising an amino acid mixture consisting of glycine, alanine, valine, leucine, isoleucine, serine, threonine, aspartic acid, glutamic acid, methionine, lysine, hydroxylysine, arginine, histidine, phenylalanine, tyrosine, proline and hydroxyproline; patent document 4 discloses a moisturizing agent characterized by containing 1 or 2 or more active ingredients selected from (a) amino acids having a positive hydropathic Index (hydropathic Index) and (B) menthol, menthol derivatives, and camphorquinone.
On the other hand, vanillyl alcohol butyl ether is generally synthesized from components contained in vanilla beans, and thus has an excellent warm-feeling effect, and a conventional reduction-weight cosmetic or the like for use in the body has been used.
For example, patent document 5 discloses a cold feeling agent composition having an excellent effect of sustaining cold feeling, which contains at least 1 kind of carboxylic acid esters of menthol or the like represented by a specific formula; patent document 6 discloses a liquid oral composition containing: (A) isopropyl methyl phenol, (B) allantoin, (C) polyoxyethylene hydrogenated castor oil with an average addition mole number of ethylene oxide of 40 to 100 moles, (D) a combination of citric acid and an alkaline agent other than citrate or a combination of citrate and citric acid or an acid other than citric acid, wherein the amount of the component (C) is 0.10 to 1.0 mass%, the mass ratio of (C)/(B) is 5 to 30, the pH of the composition is 4.0 to 6.2, and the composition further contains (E) at least 1 selected from the group consisting of spilanthol, vanillyl butyl ether and capsaicin; patent document 7 discloses a toothpaste composition containing: (a) sodium chloride, (b) at least 1 selected from menthol, peppermint oil and peppermint oil, (c) monomenthyl succinate, (d) a surfactant, and the compounding amount of (c) monomenthyl succinate is 0.03 to 1% by mass, the composition further contains at least 1 selected from (e-1) and (e-2), (e-1) vanillyl butyl ether and/or spilanthol, (e-2) an essential oil or extract of a plant selected from black pepper, hot pepper, ginger; patent document 8 discloses a weight-reducing composition comprising a blood circulation-promoting agent selected from the group consisting of amebic extract, piper nigrum extract, gentian extract, mustard extract, capsicum extract, ginger extract, ginseng extract, ginkgo biloba extract, arnica extract, safflower extract, japanese gentian extract, melilot extract, cannabis extract, camphor and derivatives thereof, sabinol and derivatives thereof, tocopherol and derivatives thereof, nicotinic acid and derivatives thereof, gamma-oryzanol and derivatives thereof, vanillyl alcohol butyl ether, and sodium bicarbonate, and an amino acid selected from the group consisting of leucine, isoleucine, valine, tryptophan, lysine, methionine, phenylalanine, threonine, valine, leucine, isoleucine, and sodium bicarbonate, 1 or more than 2 of histidine and arginine.
Documents of the prior art
Patent document
Patent document 1: international publication No. 2010/050168 pamphlet
Patent document 2: japanese patent laid-open publication No. 2005-247738
Patent document 3: japanese patent laid-open No. 2007-51087
Patent document 4: japanese patent laid-open publication No. 2013-227286
Patent document 5: japanese patent laid-open publication No. 2015-38204
Patent document 6: japanese laid-open patent publication No. 2010-143889
Patent document 7: japanese patent laid-open publication No. 2010-37318
Patent document 8: japanese patent laid-open No. 2008-69134
Disclosure of Invention
Problems to be solved by the invention
However, the techniques described in patent documents 1 to 4 relate to amino acids such as valine, isoleucine and leucine, and the use of these amino acids in combination with vanillyl alcohol butyl ether has not been studied at all. The techniques described in patent documents 1 to 4 are not inventions that can provide an external preparation for facial skin containing an amino acid that is low in irritation and has a high effect of improving facial wrinkles including the periphery of the eye.
The technique described in patent document 5 focuses on the effect of vanillyl alcohol butyl ether on the temperature sensation, and is not an invention capable of improving the effect of improving facial wrinkles including the periphery of the eyes. Further, the techniques described in patent documents 6 and 7 relate to oral compositions and toothpaste compositions, and do not mention the effect of improving facial wrinkles including the periphery of the eyes by combining with amino acids. Further, although the technique described in patent document 8 describes a combination of an amino acid such as valine, isoleucine or leucine and vanillyl alcohol butyl ether, it is always the only composition for reducing weight, and it is described in the claims, but the examples and the like do not describe any specific effect, and do not mention the effect of improving facial wrinkles including the eye periphery.
Accordingly, an object of the present invention is to solve the above-described problems of the prior art and to provide an external preparation for facial skin containing an amino acid which is low in irritation and has a high effect of improving facial wrinkles including the periphery of the eyes.
Means for solving the problems
The present inventors have conducted extensive studies to solve the above problems and as a result, have found that the above object can be achieved by blending a specific amino acid and vanillyl alcohol butyl ether, and have completed the present invention.
That is, the external preparation for facial skin containing an amino acid of the present invention is characterized by containing: (A) amino acids (A) are valine, leucine and isoleucine, and vanillyl alcohol butyl ether (B).
The external preparation for facial skin containing an amino acid of the present invention is preferably: the amino acid (A) contains 0.1-2.0 mass% of valine, 0.1-4.0 mass% of leucine, and 0.1-2.0 mass% of isoleucine, and the amino acid (B) contains 0.001-1.0 mass% of vanillyl alcohol butyl ether.
Furthermore, the external facial skin preparation containing an amino acid of the present invention preferably contains (C) an imidazole peptide, and preferably contains (D) elastin.
The external preparation for facial skin containing an amino acid of the present invention is preferably for use around the eyes.
ADVANTAGEOUS EFFECTS OF INVENTION
According to the present invention, there can be provided an external preparation for facial skin containing an amino acid, which is low in irritation and has a high effect of improving facial wrinkles including the periphery of the eye.
Detailed Description
The external preparation for facial skin containing amino acids according to 1 example of the present invention will be specifically described below.
The external preparation for facial skin containing an amino acid according to the present example is characterized by containing (a) an amino acid and (B) vanillyl alcohol butyl ether, wherein the amino acid (a) is valine, leucine, and isoleucine. Thus, the external preparation for facial skin containing an amino acid can be provided which has low irritation and a high effect of improving facial wrinkles including the periphery of the eye. In the present example, "containing" means that the components are contained in the formulation, and is not dependent on the addition method or step.
In the present example, valine, leucine and isoleucine are not particularly limited as long as they are usable in general external preparations and the like, and examples thereof include: L-Valine (trade name), L-Leucine (trade name), L-Isoleucine (trade name), and the like, manufactured by Ltd.
In the present embodiment, the (B) vanillyl alcohol butyl ether is not particularly limited as long as it is a vanillyl alcohol butyl ether that can be used for a general external preparation or the like, and examples thereof include: "Vanillyl butyl ether" manufactured by high sand spices industries Co.
In the present embodiment, the amino acid (a) preferably contains valine 0.1 to 2.0 mass%, leucine 0.1 to 4.0 mass%, and isoleucine 0.1 to 2.0 mass%, and preferably contains vanillyl alcohol butyl ether 0.001 to 1.0 mass%; preferably, the compound contains valine 0.5-1.0 mass%, leucine 0.5-2.0 mass%, and isoleucine 0.5-1.0 mass%, and contains vanillyl alcohol butyl ether 0.01-0.7 mass%. Further, it is particularly preferable that the composition contains (B) vanillyl alcohol butyl ether in an amount of 0.1 to 0.5 mass%. By setting the content to the above range, it is possible to provide an external preparation for facial skin containing an amino acid, which is less irritant and has a higher effect of improving facial wrinkles including the periphery of the eyes. In addition, when the amount of the (B) vanillyl alcohol butyl ether to be blended is increased, the amount may cause irritation, but the occurrence of irritation can be suppressed by combining the (B) vanillyl alcohol butyl ether with an amino acid in the above range.
In addition, the external preparation for facial skin containing amino acids of the present example preferably contains valine, leucine, and isoleucine at a content ratio of 1: 2: 1; particularly preferably, valine is contained in an amount of 0.5% by mass, leucine is contained in an amount of 1.0% by mass, and isoleucine is contained in an amount of 0.5% by mass. By setting the leucine to a blending ratio of about 2 times that of valine and isoleucine, the anti-fatigue effect of muscles and the like by applying an external preparation for facial skin containing an amino acid can be further improved, and the wrinkle-improving effect can be improved.
Furthermore, the external preparation for facial skin containing an amino acid according to the present example preferably contains (C) an imidazole peptide. (C) Imidazole peptide is a substance rich in the muscle of birds such as bonito, tuna, and migratory birds. The imidazole peptide (C) is not particularly limited as long as it can be used in a general external preparation or the like, and examples thereof include: carnosine, anserine, and snake carnosine, and may contain 1 or more than 2 of them. Specifically, there may be mentioned: and Amelox (trade name) manufactured by holstein GmbH & co.kg, Symrise co., DRAGOSINE (trade name) manufactured by ltd, and monomeric carnosine, anserine, and sercarnosine. By containing (C) an imidazole peptide, the wrinkle-improving effect can be further improved.
The amount of the imidazole peptide (C) to be blended is preferably 0.01 to 5% by mass, more preferably 0.1 to 3% by mass, and still more preferably 1 to 2% by mass. This can further improve the wrinkle-improving effect.
The external preparation for facial skin containing an amino acid according to the present embodiment preferably contains (D) Elastin, (D) Elastin is a protein with elastic fiber property, and the above-mentioned (D) Elastin is not particularly limited as long as it is an Elastin that can be used in general external preparations and the like, and for example, Elastin derived from animals such as cattle, tuna, and salmon, and powdery Elastin derived from animals and fish, such as Hydrolysis Elastin (trade name), Hydrolysis α -Elastin (trade name), and elasean (trade name), manufactured by gakko corporation, can be used.
The amount of elastin (D) is preferably 0.001 to 5% by mass, more preferably 0.1 to 2% by mass. This can further improve the wrinkle-improving effect.
The external preparation for facial skin containing an amino acid according to the present embodiment preferably contains an acrylamide-based water-soluble thickener. The acrylamide-based water-soluble thickener is not particularly limited as long as it can be used for a general external preparation or the like, and examples thereof include: (hydroxyethyl acrylate/sodium acryloyldimethyltaurate) copolymer, (sodium acrylate/sodium acryloyldimethyltaurate) copolymer, (ammonium acryloyldimethyltaurate/VP) copolymer, (ammonium acryloyldimethyltaurate/behenyl methacrylate polyether-25) crosslinked polymer, etc., among which (hydroxyethyl acrylate/sodium acryloyldimethyltaurate) copolymer, (sodium acrylate/sodium acryloyldimethyltaurate) copolymer is particularly preferable, and 1 or 2 or more selected from acrylamide-based water-soluble thickeners can be used. Further, as the acrylamide-based water-soluble thickener, specifically, as the (hydroxyethyl acrylate/sodium acryloyldimethyltaurate) copolymer, SEPIPLUS S (trade name), SEPINOV EMT10 (trade name), SIMULGEL NS (trade name) manufactured by SEPPIC corporation can be cited, as the (sodium acrylate/sodium acryloyldimethyltaurate) copolymer, SIMULGEL EG (trade name) manufactured by SEPPIC corporation can be cited, as the (ammonium acryloyldimethyltaurate/VP) copolymer, aristoflex vc (trade name) manufactured by Clariant corporation can be cited, as the (ammonium acryloyldimethyltaurate methacrylate beheneth-25) crosslinked polymer, there can be cited: aristoflex HMB (trade name) manufactured by Clariant corporation, and the like. By adding the acrylamide-based water-soluble thickener, the stability of the dissolution of valine, leucine, and isoleucine in the external facial skin preparation containing the amino acid can be improved, and the wrinkle-improving effect, the anti-fatigue effect, and the like, which are brought about by applying the external facial skin preparation containing the amino acid, can be further improved.
Furthermore, the external preparation for facial skin containing an amino acid according to the present example is preferably prepared by mixing and dissolving at least 1 selected from the group consisting of PEG-20 methylglucamine sesquistearate and PEG-20 methylglucamine dioleate. The PEG-20-methylglucamine sesquistearate and PEG-20-methylglucamine dioleate are not particularly limited as long as they can be used for general external preparations and the like, and examples thereof include: glucimate SSE-20 (trade name), glucimate DOE-120 (trade name), manufactured by Japan Lubrizol Corporation, and the like. This makes it possible to improve the solubility stability of valine, leucine, and isoleucine in the external facial skin preparation containing the amino acid, and to further improve the wrinkle-improving effect, the anti-fatigue effect, and the like, which are brought about by applying the external facial skin preparation containing the amino acid.
The external preparation for facial skin containing an amino acid of the present example is a substance having low irritation and a high wrinkle-improving effect, and therefore is suitable for use as an external preparation for facial skin (face), is particularly preferable for the eye area where wrinkles are conspicuously generated, and can be used for eye creams, cosmetic solutions for the eye area, and the like. Further, the skin external preparation is a substance that can be applied to the human body and the like, and can be used for cosmetics, quasi drugs, and the like. Therefore, the cosmetic and the like include basic cosmetics such as a pack and makeup cosmetics.
In the present embodiment, other components and the like may be added as appropriate within a range in which the above-described effects are not impaired. Examples of the optionally blended components other than the above include those usually blended in skin external preparations and the like, for example: oily component, humectant, antioxidant, antiseptic, perfume, various vitamins, chelating agent, colorant, ultraviolet absorbent, medicinal component, inorganic salt, etc.
The following will explain in further detail by using examples 1 to 10, but the present invention is not limited to these examples. The numerical values in the formulation represent mass%.
Examples
(example 1, comparative examples 1 and 2)
The skin external preparations of example 1 and comparative example 1 were prepared according to the formulations shown in table 1 below. The obtained external skin preparations of example 1, comparative example 1 and comparative example 2 were subjected to the wrinkle improvement test described below, and are shown in table 1. In addition, the following skin irritation test was performed. The numerical values in the formulation represent mass%. In table 1, color 1 is sepippulus S (trade name) manufactured by SEPPIC corporation.
[ Table 1]
(wrinkle improvement test)
The test was carried out according to "evaluation criteria for anti-wrinkle article for obtaining novel efficacy (japanese society for cosmetics (vol.30, No.4, p.316-332, 2006)", 20 adult women with wrinkle grades of 1 to 3 were taken as subjects, the skin external preparations of examples and comparative examples were applied to the skin of one side of the canthus of the face continuously for one month every day, and then the improvement effect of wrinkles was investigated.
(evaluation criteria)
◎ (good), the number of people who confirmed the improvement was 15 or more
○ (slightly better), the number of people who have been confirmed to be improved is more than 10 to less than 15
△ (slightly worse), the number of people who were confirmed to have improved is 5 or more to less than 10
× poor results the number of people who confirmed improvement was less than 5
(skin irritation test)
For 20 women aged 20 to 30 years, the external preparations for skin of examples and comparative examples were applied to the skin of the canthus on one side of the face every day for one month continuously, and then the skin irritation was investigated. The following 5 grades of the presence or absence of the stimulation were evaluated in comparison with the uncoated portion, and based on the average score, the judgment was made based on the following criteria.
(5 rating)
And 5, dividing: very good (no irritation)
And 4, dividing: slightly better
And 3, dividing: can be used for
And 2, dividing: general purpose
1 minute: poor (with stimulation)
(evaluation criteria 2)
Average score greater than 4 points ◎ (good)
Average score greater than 3 and less than 4 points ○ (slightly better)
An average score of △ (slightly worse) of more than 2 and 3 points or less
Average score below 2 points × (poor)
As is clear from the results in table 1, the skin external preparation of example 1 was effective in improving wrinkles in 18 adult women. On the other hand, the external skin preparations of comparative examples 1 and 2 exhibited an improvement effect only in 2 adult women, and the wrinkle-improving effect was poor. The skin external preparation of example 1 was low in irritation, with an average skin irritation evaluation score of 4.8. On the other hand, the skin external preparation of comparative example 1 was evaluated for skin irritation at an average score of 4.9, and low irritation, but comparative example 2 was evaluated for skin irritation at an average score of 3.5, which was greater than that of example 1.
(example 2)
The face mask of example 2 was prepared according to the formulation shown in table 2 below. The obtained mask agent of example 2 was subjected to the wrinkle improvement test and the skin irritation test. The numerical values in the formulation represent mass%. In table 2, color 2 is Tornare (trade name) manufactured by forest products.
[ Table 2]
| Name of composition | Compounding amount (% by mass) |
| Purified water | 81.70 |
| Glycerol | 5.00 |
| Pentanediol | 2.00 |
| Carbomer | 0.50 |
| Arginine | 0.70 |
| Phenoxyethanol | 0.50 |
| Tornare※2 | 5.00 |
| Elastin (powder) | 0.50 |
| Anserine | 1.00 |
| Carnosine | 1.00 |
| L-valine | 0.50 |
| L-leucine | 1.00 |
| L-isoleucine | 0.50 |
| Vanillyl alcohol butyl ether | 0.10 |
| Total of | 100.00 |
The facial mask of example 2 was improved in 19 adult women, and the wrinkle-improving effect was excellent. The average score of the evaluation of skin irritation of the mask of example 2 was 4.9 points, which was low irritation.
(example 3)
The skin preparation for external use of example 3 was prepared according to the formulation shown in table 3 below. The obtained external skin preparation of example 3 was subjected to the wrinkle improvement test described above. In table 3, reference numeral 1 denotes sepippulus S (trade name) manufactured by SEPPIC corporation.
[ Table 3]
The skin external preparation of example 3 was effective in improving wrinkles in 19 adult women.
(example 4)
The face mask of example 4 was prepared according to the formulation of table 4 below. The obtained facial mask of example 4 was subjected to the wrinkle improvement test described above. In table 4, color 2 is Tornare (trade name) manufactured by lins inc.
[ Table 4]
| Name of composition | Compounding amount (% by mass) |
| Purified water | 79.80 |
| Glycerol | 5.00 |
| Pentanediol | 2.00 |
| Carbomer | 0.50 |
| Arginine | 0.70 |
| Phenoxyethanol | 0.50 |
| Tornare※2 | 5.00 |
| Elastin (powder) | 0.50 |
| Anserine | 1.00 |
| Carnosine | 1.00 |
| L-valine | 0.50 |
| L-leucine | 1.00 |
| L-isoleucine | 0.50 |
| N-acetylglucosamine | 1.00 |
| Vanillyl alcohol butyl ether | 1.00 |
| Total of | 100.00 |
The facial mask of example 4 was improved in 19 adult women, and the wrinkle-improving effect was excellent.
(example 5)
The lotions of example 5 were prepared according to the formulation of table 5 below. The obtained astringent of example 5 was subjected to the wrinkle improvement test and the skin irritation test described above.
[ Table 5]
| Name of composition | Compounding amount (% by mass) |
| Purified water | 71.29 |
| 1, 3-butanediol | 6.00 |
| Glycerol | 4.00 |
| Oleyl alcohol | 0.10 |
| POE (20) sorbitan monostearate | 0.50 |
| POE (15) lauryl Ether | 0.50 |
| Ethanol | 10.00 |
| P-hydroxybenzoic acid methyl ester | 0.30 |
| Elastin (powder) | 0.50 |
| Anserine | 1.00 |
| Carnosine | 1.00 |
| L-valine | 1.20 |
| L-leucine | 2.40 |
| L-isoleucine | 1.20 |
| Vanillyl alcohol butyl ether | 0.01 |
| Total of | 100.00 |
The astringent of example 5 was improved in 17 adult women, and the wrinkle-improving effect was excellent. The skin irritation evaluation of the cosmetic liquid of example 5 was 4.95 points on average, and the skin irritation was low.
(example 6)
The lotions of example 6 were prepared according to the formulation of table 6 below. The obtained astringent of example 6 was subjected to the wrinkle improvement test described above.
[ Table 6]
| Name of composition | Compounding amount (% by mass) |
| Purified water | 64.20 |
| 1, 3-butanediol | 6.00 |
| Glycerol | 5.00 |
| PEG 4000 | 3.00 |
| Olive oil | 0.50 |
| POE (20) sorbitan monostearate | 1.50 |
| POE (5) oleyl alcohol ether | 0.30 |
| Ethanol | 10.00 |
| P-hydroxybenzoic acid methyl ester | 0.30 |
| Elastin (powder) | 0.50 |
| Anserine | 1.00 |
| Carnosine | 1.00 |
| L-valine | 1.00 |
| L-leucine | 2.00 |
| L-isoleucine | 1.00 |
| N-acetylglucosamine | 2.00 |
| Vanillyl alcohol butyl ether | 0.70 |
| Total of | 100.00 |
The astringent of example 6 was improved in 17 adult women, and the wrinkle-improving effect was excellent.
(example 7)
The cream of example 7 was made according to the formulation of table 7 below. The obtained cream of example 7 was subjected to the wrinkle improvement test and the skin irritation test described above.
[ Table 7]
| Name of composition | Compounding amount (% by mass) |
| Purified water | 48.80 |
| 1, 3-butanediol | 6.00 |
| PEG1500 | 4.00 |
| Stearyl alcohol | 6.00 |
| Stearic acid | 2.00 |
| Hydrogenated lanolin | 4.00 |
| Squalane | 9.00 |
| Octyl dodecanol | 10.00 |
| POE (25) cetyl Ether | 3.00 |
| Glyceryl monostearate | 2.00 |
| P-hydroxybenzoic acid methyl ester | 0.30 |
| Phenoxyethanol | 0.30 |
| Elastin (powder) | 0.50 |
| Anserine | 1.00 |
| Carnosine | 1.00 |
| L-valine | 0.50 |
| L-leucine | 1.00 |
| L-isoleucine | 0.50 |
| Vanillyl alcohol butyl ether | 0.10 |
| Total of | 100.00 |
The cream of example 7 was improved in 18 adult women, and the wrinkle-improving effect was good. The average score of the evaluation of skin irritation of the cream of example 7 was 4.7 points, which is low irritation.
(example 8)
The cream of example 8 was made according to the formulation of table 8 below. The obtained cream of example 8 was subjected to the wrinkle improvement test and the skin irritation test described above.
[ Table 8]
| Name of composition | Compounding amount (% by mass) |
| Purified water | 65.49 |
| 1, 3-butanediol | 5.00 |
| Stearyl alcohol | 4.00 |
| Stearic acid | 8.00 |
| Stearic acid butyl ester | 6.00 |
| Glyceryl monostearate | 2.00 |
| Potassium hydroxide | 0.40 |
| P-hydroxybenzoic acid methyl ester | 0.30 |
| Phenoxyethanol | 0.30 |
| Elastin (powder) | 0.50 |
| Anserine | 1.00 |
| Carnosine | 1.00 |
| L-valine | 1.00 |
| L-leucine | 2.00 |
| L-isoleucine | 1.00 |
| N-acetylglucosamine | 2.00 |
| Vanillyl alcohol butyl ether | 0.01 |
| Total of | 100.00 |
The cream of example 8 was improved in 19 adult women, and the wrinkle-improving effect was good. The average score of the evaluation of skin irritation of the cream of example 8 was 4.9 points, which is low irritation.
(example 9)
The cosmetic liquid of example 9 was prepared according to the formulation of table 9 below. The obtained cosmetic liquid of example 9 was subjected to the wrinkle improvement test and the skin irritation test described above.
[ Table 9]
| Name of composition | Compounding amount (% by mass) |
| Purified water | 64.90 |
| 1, 3-butanediol | 5.00 |
| Sorbitol | 8.00 |
| PEG1500 | 7.00 |
| Olive oil | 0.20 |
| POE oleyl alcohol ether | 1.00 |
| Ethanol | 7.00 |
| P-hydroxybenzoic acid methyl ester | 0.30 |
| Elastin (powder) | 0.50 |
| Anserine | 1.00 |
| Carnosine | 1.00 |
| L-valine | 1.00 |
| L-leucine | 2.00 |
| L-isoleucine | 1.00 |
| Vanillyl alcohol butyl ether | 0.10 |
| Total of | 100.00 |
The skin-care liquid of example 9 was effective in improving wrinkles in 17 adult women. The skin irritation evaluation of the cosmetic liquid of example 9 was 4.7 points on average, and the skin irritation was low.
(example 10)
The cosmetic liquid of example 10 was prepared according to the formulation of table 10 below. The obtained cosmetic liquid of example 10 was subjected to the wrinkle improvement test described above.
[ Table 10]
| Name of composition | Compounding amount (% by mass) |
| Purified water | 64.70 |
| 1, 3-butanediol | 6.00 |
| Stearic acid | 3.00 |
| Cetyl alcohol | 1.00 |
| Hydrogenated lanolin | 3.00 |
| Squalane | 5.00 |
| Stearic acid-2-ethylhexyl ester | 3.00 |
| POE cetyl alcohol ether | 2.00 |
| Glyceryl monostearate | 2.00 |
| Triethanolamine | 1.00 |
| P-hydroxybenzoic acid methyl ester | 0.30 |
| Elastin (powder) | 0.50 |
| Anserine | 1.00 |
| Carnosine | 1.00 |
| L-valine | 1.00 |
| L-leucine | 2.00 |
| L-isoleucine | 1.00 |
| N-acetylglucosamine | 2.00 |
| Vanillyl alcohol butyl ether | 0.50 |
| Total of | 100.00 |
The cosmetic liquid of example 10 was effective in improving wrinkles in 18 adult women.
Claims (3)
1. An external preparation for facial skin containing an amino acid, which is characterized by comprising: (A) amino acid and (B) vanillyl alcohol butyl ether,
the amino acid (A) is valine, leucine and isoleucine,
the amino acid (A) contains 0.1-2.0 mass% of valine, 0.1-4.0 mass% of leucine, and 0.1-2.0 mass% of isoleucine, and the amino acid (B) contains 0.001-1.0 mass% of vanillyl alcohol butyl ether.
2. The external preparation for facial skin containing an amino acid according to claim 1, further comprising either or both of (C) an imidazole peptide and (D) elastin.
3. The external preparation for skin on face containing an amino acid according to claim 1 or 2, which is an external preparation for skin around the eyes.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015-242786 | 2015-12-14 | ||
| JP2015242786A JP5966231B1 (en) | 2015-12-14 | 2015-12-14 | Amino acid-containing facial skin preparation |
| PCT/JP2016/086566 WO2017104537A1 (en) | 2015-12-14 | 2016-12-08 | Amino acid-containing external skin preparation for face |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107708659A CN107708659A (en) | 2018-02-16 |
| CN107708659B true CN107708659B (en) | 2020-07-03 |
Family
ID=56692755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680038189.0A Expired - Fee Related CN107708659B (en) | 2015-12-14 | 2016-12-08 | External preparation for facial skin containing amino acids |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JP5966231B1 (en) |
| KR (1) | KR20180010255A (en) |
| CN (1) | CN107708659B (en) |
| HK (1) | HK1246172A1 (en) |
| TW (1) | TWI641391B (en) |
| WO (1) | WO2017104537A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7441042B2 (en) * | 2016-12-02 | 2024-02-29 | シムライズ アーゲー | cosmetic blend |
| JP2021520351A (en) * | 2018-04-04 | 2021-08-19 | ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド | Composition for treating the skin |
| WO2022025109A1 (en) * | 2020-07-29 | 2022-02-03 | 味の素株式会社 | Wrinkle-improving composition |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101166427A (en) * | 2005-04-22 | 2008-04-23 | 烧津水产化学工业株式会社 | Taste improving agent for food and beverage containing potassium chloride, process for producing food and beverage containing potassium chloride and food and beverage containing potassium chloride pro |
| CN103734716A (en) * | 2013-12-16 | 2014-04-23 | 无锡金维氨生物科技有限公司 | Branched chain amino acid |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3121957B2 (en) * | 1993-03-03 | 2001-01-09 | 鐘紡株式会社 | Anti-aging skin cosmetics |
| EP0806947A4 (en) * | 1995-02-03 | 1998-10-14 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
| JP2001115197A (en) * | 1999-10-14 | 2001-04-24 | Take:Kk | Soap |
| JP2002020277A (en) * | 2000-06-30 | 2002-01-23 | Lion Corp | External preparation composition |
| JP4077282B2 (en) * | 2001-09-21 | 2008-04-16 | 花王株式会社 | Vanillyl ether derivative |
| JP2004161709A (en) * | 2002-11-15 | 2004-06-10 | Pola Chem Ind Inc | Cosmetic kit for ameliorating edema |
| JP4138679B2 (en) * | 2004-02-25 | 2008-08-27 | 株式会社資生堂 | Irritation relief agent |
| JP4809161B2 (en) * | 2006-08-29 | 2011-11-09 | 富士フイルム株式会社 | Topical skin preparation |
| JP5072296B2 (en) * | 2006-09-15 | 2012-11-14 | 株式会社ノエビア | Slimming composition |
| JP2011042588A (en) * | 2009-08-19 | 2011-03-03 | Kenzo Ito | Moisturizing cosmetic |
-
2015
- 2015-12-14 JP JP2015242786A patent/JP5966231B1/en active Active
-
2016
- 2016-12-08 KR KR1020177036995A patent/KR20180010255A/en not_active Application Discontinuation
- 2016-12-08 CN CN201680038189.0A patent/CN107708659B/en not_active Expired - Fee Related
- 2016-12-08 WO PCT/JP2016/086566 patent/WO2017104537A1/en active Application Filing
- 2016-12-12 TW TW105141102A patent/TWI641391B/en not_active IP Right Cessation
-
2018
- 2018-05-02 HK HK18105681.3A patent/HK1246172A1/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101166427A (en) * | 2005-04-22 | 2008-04-23 | 烧津水产化学工业株式会社 | Taste improving agent for food and beverage containing potassium chloride, process for producing food and beverage containing potassium chloride and food and beverage containing potassium chloride pro |
| CN103734716A (en) * | 2013-12-16 | 2014-04-23 | 无锡金维氨生物科技有限公司 | Branched chain amino acid |
Non-Patent Citations (1)
| Title |
|---|
| 防治皱纹的策略;弓长;《服务科技》;20001231;8-9 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017109927A (en) | 2017-06-22 |
| KR20180010255A (en) | 2018-01-30 |
| TWI641391B (en) | 2018-11-21 |
| TW201720418A (en) | 2017-06-16 |
| CN107708659A (en) | 2018-02-16 |
| HK1246172A1 (en) | 2018-09-07 |
| JP5966231B1 (en) | 2016-08-10 |
| WO2017104537A1 (en) | 2017-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3503884B2 (en) | Cosmetics | |
| JP6017953B2 (en) | Skin external composition | |
| KR20010014687A (en) | Oily material composition | |
| CN107708659B (en) | External preparation for facial skin containing amino acids | |
| JP4088436B2 (en) | Skin preparation | |
| JP5550863B2 (en) | Cosmetics | |
| JP2002173449A (en) | Hair-growing agent | |
| JP2002193755A (en) | Antidandruff and anti-itching hair cosmetic and hair- shampooing cosmetic | |
| JP2019137695A (en) | Method for permeation of skin active ingredient | |
| CN111818905A (en) | Topical compositions | |
| US10695276B2 (en) | Composition containing glycerol and glycine | |
| JP2006199648A (en) | Composition for hair | |
| JP6052181B2 (en) | Cosmetics | |
| JPH07101836A (en) | Hair treating agent | |
| JP2013249301A (en) | Composition for external use | |
| JPH05301812A (en) | Skin external preparation | |
| JP2021138683A (en) | Composition for external use | |
| JP2004315442A (en) | Gray hair-preventing/improving agent | |
| JP2006008610A (en) | Preparation for external use | |
| JP2000063255A (en) | Preparation for external use for skin | |
| JP5734686B2 (en) | Skin external composition | |
| WO2020158643A1 (en) | External preparation | |
| JP7214075B2 (en) | cosmetic composition | |
| JP2003146836A (en) | Cosmetic | |
| JP2024083776A (en) | Composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1246172 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200703 |